DOUBLE PRO-TECT Alport试验:达格列净治疗年轻Alport综合征患者的随机对照试验方案
该文报告了一项多中心、随机、双盲、安慰剂对照试验的方案,旨在评估SGLT2抑制剂达格列净在10-39岁Alport综合征患者中的安全性和疗效。主要终点为48周时尿白蛋白与肌酐比值(UACR)较基线的变化,关键次要终点为52周时eGFR变化。
要点
- DOUBLE PRO-TECT Alport试验纳入10-39岁经基因检测或肾活检确诊的Alport综合征患者。
- 患者需在稳定使用最大耐受剂量RAS抑制剂>3个月基础上,UACR>300 mg/g(儿童)或>500 mg/g(成人)。
- 按2:1随机接受达格列净10 mg/日或安慰剂治疗48周,主要终点为UACR变化。
核心结论
- DOUBLE PRO-TECT Alport试验将评估SGLT2抑制剂能否安全降低年轻Alport综合征患者UACR变化,作为CKD进展标志物。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,纳入10-39岁Alport综合征患者。
- 参与者需经基因检测或肾活检确诊,并稳定使用最大耐受剂量RAS抑制剂>3个月。
- 按2:1比例随机分配到达格列净10 mg/日组或安慰剂组,治疗48周。
- 主要终点为48周UACR较基线变化,关键次要终点为52周eGFR变化。
关键数值与推荐
- 入组标准:儿童UACR>300 mg/g,成人UACR>500 mg/g。
- 治疗剂量:达格列净10 mg/日,疗程48周。
- 主要疗效分析采用混合模型重复测量,在意向治疗全分析集中进行。
- 敏感性分析采用基于参照的多重插补。
临床怎么用
- 该试验结果将为SGLT2抑制剂在年轻Alport综合征患者中的应用提供证据。
- 目前SGLT2抑制剂在儿童和年轻成人早期CKD中的获益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium-glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs). Whether benefits extend to children, teenagers and young adults with early-stage CKD is unknown. For this reason, the DOUBLE PRO-TECT Alport trial (NCT05944016) will study the progression of albuminuria in young patients with Alport syndrome (AS), the most common hereditary CKD, to assess the safety and efficacy of the SGLT2 inhibitor dapagliflozin. Patients living with AS and chronically elevated albuminuria have a high risk of kidney failure before the age of 50 years. METHODS: DOUBLE PRO-TECT Alport is a multicentre, randomized, double-blind, placebo-controlled trial. Participants (ages 10-39 years) must have a diagnosis of AS by genetic testing or kidney biopsy, be on a stable (>3 months) maximum tolerated dose of a renin-angiotensin system inhibitor and have a urinary albumin:creatinine ratio (UACR) of >300 mg/g (paediatric) or >500 mg/g (adult).Eligible participants will be randomly assigned at a 2:1 ratio to 48 weeks of treatment with dapaglifozin 10 mg/day or matched placebo. Most participants are expected to be children with a normal estimated glomerular filtration rate (eGFR). In addition to safety, the primary (change in UACR from baseline to week 48) and key secondary (eGFR change from baseline to week 52) efficacy outcomes will be analysed with a mixed model repeated measures approach. Efficacy analyses will be performed primarily in the full analysis set according to the intention-to-treat principle. A sensitivity analysis will be performed using reference-based multiple imputation. CONCLUSION: DOUBLE PRO-TECT Alport will assess whether SGLT2 inhibitors can safely reduce the UACR change from baseline as a marker for progression of CKD in young patients living with AS.
引用
- Gross O, Boeckhaus J, Weber LT, et al. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol Dial Transplant. 2025. PMID: 39122650. doi:10.1093/ndt/gfae180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。